These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 28637689)
1. Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer. Yang WL; Gentry-Maharaj A; Simmons A; Ryan A; Fourkala EO; Lu Z; Baggerly KA; Zhao Y; Lu KH; Bowtell D; Jacobs I; Skates SJ; He WW; Menon U; Bast RC; Clin Cancer Res; 2017 Oct; 23(19):5912-5922. PubMed ID: 28637689 [No Abstract] [Full Text] [Related]
2. Comparison of Longitudinal CA125 Algorithms as a First-Line Screen for Ovarian Cancer in the General Population. Blyuss O; Burnell M; Ryan A; Gentry-Maharaj A; Mariño IP; Kalsi J; Manchanda R; Timms JF; Parmar M; Skates SJ; Jacobs I; Zaikin A; Menon U Clin Cancer Res; 2018 Oct; 24(19):4726-4733. PubMed ID: 30084833 [No Abstract] [Full Text] [Related]
3. Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer. Simmons AR; Fourkala EO; Gentry-Maharaj A; Ryan A; Sutton MN; Baggerly K; Zheng H; Lu KH; Jacobs I; Skates S; Menon U; Bast RC Cancer Prev Res (Phila); 2019 Jun; 12(6):391-400. PubMed ID: 30967390 [TBL] [Abstract][Full Text] [Related]
4. Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials. Skates SJ; Greene MH; Buys SS; Mai PL; Brown P; Piedmonte M; Rodriguez G; Schorge JO; Sherman M; Daly MB; Rutherford T; Brewster WR; O'Malley DM; Partridge E; Boggess J; Drescher CW; Isaacs C; Berchuck A; Domchek S; Davidson SA; Edwards R; Elg SA; Wakeley K; Phillips KA; Armstrong D; Horowitz I; Fabian CJ; Walker J; Sluss PM; Welch W; Minasian L; Horick NK; Kasten CH; Nayfield S; Alberts D; Finkelstein DM; Lu KH Clin Cancer Res; 2017 Jul; 23(14):3628-3637. PubMed ID: 28143870 [No Abstract] [Full Text] [Related]
5. Validation of LRG1 as a potential biomarker for detection of epithelial ovarian cancer by a blinded study. Wu J; Yin H; Zhu J; Buckanovich RJ; Thorpe JD; Dai J; Urban N; Lubman DM PLoS One; 2015; 10(3):e0121112. PubMed ID: 25799488 [TBL] [Abstract][Full Text] [Related]
6. Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study. Rosenthal AN; Fraser LSM; Philpott S; Manchanda R; Burnell M; Badman P; Hadwin R; Rizzuto I; Benjamin E; Singh N; Evans DG; Eccles DM; Ryan A; Liston R; Dawnay A; Ford J; Gunu R; Mackay J; Skates SJ; Menon U; Jacobs IJ; J Clin Oncol; 2017 May; 35(13):1411-1420. PubMed ID: 28240969 [TBL] [Abstract][Full Text] [Related]
7. Highly accurate detection of ovarian cancer using CA125 but limited improvement with serum matrix-assisted laser desorption/ionization time-of-flight mass spectrometry profiling. Tiss A; Timms JF; Smith C; Devetyarov D; Gentry-Maharaj A; Camuzeaux S; Burford B; Nouretdinov I; Ford J; Luo Z; Jacobs I; Menon U; Gammerman A; Cramer R Int J Gynecol Cancer; 2010 Dec; 20(9):1518-24. PubMed ID: 21370595 [TBL] [Abstract][Full Text] [Related]
8. Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response. Hamed EO; Ahmed H; Sedeek OB; Mohammed AM; Abd-Alla AA; Abdel Ghaffar HM Diagn Pathol; 2013 Jan; 8():11. PubMed ID: 23343214 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of human epididymis protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA) as diagnostic tools of type I and type II epithelial ovarian cancer in Japanese women. Fujiwara H; Suzuki M; Takeshima N; Takizawa K; Kimura E; Nakanishi T; Yamada K; Takano H; Sasaki H; Koyama K; Ochiai K Tumour Biol; 2015 Feb; 36(2):1045-53. PubMed ID: 25326813 [TBL] [Abstract][Full Text] [Related]
10. Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer. Clarke CH; Yip C; Badgwell D; Fung ET; Coombes KR; Zhang Z; Lu KH; Bast RC Gynecol Oncol; 2011 Sep; 122(3):548-53. PubMed ID: 21708402 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of paraneoplastic antigens reveals TRIM21 autoantibodies as biomarker for early detection of ovarian cancer in combination with autoantibodies to NY-ESO-1 and TP53. Hurley LC; Levin NK; Chatterjee M; Coles J; Muszkat S; Howarth Z; Dyson G; Tainsky MA Cancer Biomark; 2020; 27(3):407-421. PubMed ID: 32083570 [TBL] [Abstract][Full Text] [Related]
12. Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. Menon U; Ryan A; Kalsi J; Gentry-Maharaj A; Dawnay A; Habib M; Apostolidou S; Singh N; Benjamin E; Burnell M; Davies S; Sharma A; Gunu R; Godfrey K; Lopes A; Oram D; Herod J; Williamson K; Seif MW; Jenkins H; Mould T; Woolas R; Murdoch JB; Dobbs S; Amso NN; Leeson S; Cruickshank D; Scott I; Fallowfield L; Widschwendter M; Reynolds K; McGuire A; Campbell S; Parmar M; Skates SJ; Jacobs I J Clin Oncol; 2015 Jun; 33(18):2062-71. PubMed ID: 25964255 [TBL] [Abstract][Full Text] [Related]
13. p53-autoantibody may be more sensitive than CA-125 in monitoring microscopic and macroscopic residual disease after primary therapy for epithelial ovarian cancer. Häfner N; Nicolaus K; Weiss S; Frey M; Diebolder H; Rengsberger M; Dürst M; Runnebaum IB J Cancer Res Clin Oncol; 2013 Jul; 139(7):1207-10. PubMed ID: 23576021 [TBL] [Abstract][Full Text] [Related]
14. Ovarian cancer screening: development of the risk of ovarian cancer algorithm (ROCA) and ROCA screening trials. Skates SJ Int J Gynecol Cancer; 2012 May; 22 Suppl 1(Suppl 1):S24-6. PubMed ID: 22543916 [TBL] [Abstract][Full Text] [Related]
15. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer. Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570 [TBL] [Abstract][Full Text] [Related]
16. Tumor autoantibodies as biomarkers for predicting ovarian cancer recurrence. Chatterjee M; Dyson G; Levin NK; Shah JP; Morris R; Munkarah A; Tainsky MA Cancer Biomark; 2012; 11(2-3):59-73. PubMed ID: 23011153 [TBL] [Abstract][Full Text] [Related]
17. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting. Jacob F; Meier M; Caduff R; Goldstein D; Pochechueva T; Hacker N; Fink D; Heinzelmann-Schwarz V Gynecol Oncol; 2011 Jun; 121(3):487-91. PubMed ID: 21420727 [TBL] [Abstract][Full Text] [Related]
18. Development of a longitudinal two-biomarker algorithm for early detection of ovarian cancer in women with BRCA mutations. Lentz SE; Powell CB; Haque R; Armstrong MA; Anderson M; Liu Y; Jiang W; Chillemi G; Shaw S; Alvarado MM; Kushi LH; Skates SJ Gynecol Oncol; 2020 Dec; 159(3):804-810. PubMed ID: 33012551 [TBL] [Abstract][Full Text] [Related]
19. Human epididymis protein 4 antigen-autoantibody complexes complement cancer antigen 125 for detecting early-stage ovarian cancer. Yang WL; Lu Z; Guo J; Fellman BM; Ning J; Lu KH; Menon U; Kobayashi M; Hanash SM; Celestino J; Skates SJ; Bast RC Cancer; 2020 Feb; 126(4):725-736. PubMed ID: 31714597 [TBL] [Abstract][Full Text] [Related]
20. Potential effect of the risk of ovarian cancer algorithm (ROCA) on the mortality outcome of the Prostate, Lung, Colorectal and Ovarian (PLCO) trial. Pinsky PF; Zhu C; Skates SJ; Black A; Partridge E; Buys SS; Berg CD Int J Cancer; 2013 May; 132(9):2127-33. PubMed ID: 23065684 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]